BioLife Solutions (BLFS) Misses Q2 EPS by 2c

BioLife Solutions (NASDAQ: BLFS) reported Q2 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $2.56 million versus the consensus estimate of $2.48 million.

Guidance:

Management reaffirms the full-year revenue guidance for biopreservation media products, which is expected to grow between 20 - 25% over 2016, with revenue for 2017 in excess of $10 million.

Based on the financial results for the six months ended June 30th, 2017, management has revised the balance of our full-year 2017 guidance as follows:

• Gross Margin for 2017 is now expected to be between 58% to 62%, which is up from the previously provided range of 55% to 60%.
• Annual operating expenses are expected to be between $8 to $8.5 million, which is down from the previous range of $8 to $9 million.
• Positive adjusted EBITDA is now expected for the full-year of 2017.

For earnings history and earnings-related data on BioLife Solutions (BLFS) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
• Wells Fargo cuts Netflix rating on engagement risk, weak slate